Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting.
about
CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targetingThe outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyThe pathogenesis of chronic lymphocytic leukemiaNosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic Disorders.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyInhibition of infection-mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice.Small molecule inhibitors of CXCR4.A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro.The intricate role of CXCR4 in cancer.Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia CellsCo-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivoCannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation.Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic LeukemiaRole of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.Malignant B-cell intra-clonal diversification: following the yarn in the labyrinth.Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs.Targeting the B cell receptor pathway in chronic lymphocytic leukemia.Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy."Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''.Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia.The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1.A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).Modeling the chronic lymphocytic leukemia microenvironment in vitro.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Identification of potential CCR5 inhibitors through pharmacophore-based virtual screening, molecular dynamics simulation and binding free energy analysis.Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling moleculesPhenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.Lipoprotein lipase expression in unmutated CLL patients is the consequence of a demethylation process induced by the microenvironment.Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.The role of G protein-coupled receptors in lymphoid malignancies.Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia.Chemotactic Cues for NOTCH1-Dependent Leukemia.Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study
P2860
Q26849606-D3080157-2200-453E-89A9-581A2E01A54EQ26865760-0679539D-92C0-41D0-90F8-2ACB223A8BB8Q27025715-11C04FF4-5923-4C87-9A83-BB27971C6659Q30385714-3D609F01-71D4-40F4-A351-E52B498CB198Q34056568-D821F8F7-3A43-4753-9DEE-0EA9DC9EFC95Q34240404-80E2BD2E-E8EE-473B-B2E6-1A565AC58C8BQ34336857-F94A76EE-EBB9-4686-8FC5-1F83D2DB77E3Q34574987-FAF3DF6F-9457-4C97-AF6A-00DF99BE09E4Q34653811-E658A48B-67AA-43B7-809E-57376A4EC07DQ35067624-FD9952AC-8745-4915-9B3B-8DFFBFFAFBF1Q35754594-489A74F4-ACE2-4610-AA7D-791398F1C6C2Q35781372-7FEAAB3E-3153-4AC5-B34F-C21BBF39A8AAQ36036102-37113AF1-E47E-4276-99C6-1565D11773F0Q36471596-3F994491-6377-408A-ABBE-2EA2C360EBA5Q37610087-EB5A17A0-D574-44FB-BF26-779D37CAC057Q37636759-452893C6-64CF-4195-AA3F-1D3FCCC440E7Q37894085-73CFF01A-0673-4047-90D2-5B7423341F8CQ38009278-333A95C7-6DE6-4756-A226-0F94E09E43FBQ38012179-8787FC8D-333D-4CD2-BC1A-3BAAF10ADE94Q38101683-AC74B67F-2EF7-4A39-ACDD-5B59F29DB237Q38140625-86C26BB4-795C-4BCF-A0A8-A3EB5062650BQ38163044-670C87D0-6643-40C6-9C5E-F79DD5525D7BQ38171390-F67A528A-0641-4996-8D26-9F59513849CEQ38325527-567A5D5A-C649-4769-AED2-5AB679208187Q38392841-FBFB5E04-C121-4E44-B2A9-B236CED61BE3Q38984569-6040CE99-6843-4072-AE3B-55829EE2919BQ39169789-0E770B6E-4B27-4FC8-A6A7-F10EDC3DBD69Q39314390-E49A033F-2FE9-493E-A661-DB3F4160CC36Q42083503-E6D64A89-77B1-414C-A4F8-49EAA3F09A45Q43186639-8845BE25-A2BE-4507-BF43-4308B283F75FQ45384341-F1B0079F-48BE-4C0F-9B24-790BBA90ED3AQ45874243-E0C7E2AA-A727-416D-8CD9-7359FAC03FA6Q47388561-0B3FB790-5890-42A7-9982-D5848210E42CQ47960121-4D8DC80A-FB4B-4092-9736-0F8D406491A5Q51044690-E6269028-096F-44FA-8F44-BCFE50BFFF12Q55235440-ECDB8386-CD31-43F3-BA7E-3AF55F88518CQ58697794-78AB994F-3B33-471D-8AD1-6539C3EC7969
P2860
Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemokines and chemokine recep ...... towards therapeutic targeting.
@en
Chemokines and chemokine receptors in chronic lymphocytic leukemia
@nl
type
label
Chemokines and chemokine recep ...... towards therapeutic targeting.
@en
Chemokines and chemokine receptors in chronic lymphocytic leukemia
@nl
prefLabel
Chemokines and chemokine recep ...... towards therapeutic targeting.
@en
Chemokines and chemokine receptors in chronic lymphocytic leukemia
@nl
P1476
Chemokines and chemokine recep ...... towards therapeutic targeting.
@en
P2093
Jan A Burger
P304
P356
10.1016/J.SEMCANCER.2010.09.005
P577
2010-09-29T00:00:00Z